Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA6 | P23280 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | F13A1 | P00488 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9801640 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801593 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801337 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801537 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL2785093 | 0.97 | CA2 (0.40) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801795 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801792 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801304 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801743 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 | |
| SCHEMBL9801077 | 0.97 | CA2 (0.44) | CA2CA12CA9CYP1A2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387607-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | Tiba Biotech LLC (US) | 2024-06-26 | — | — | EP | claimed |
| CN-117897152-A | Nanoparticle compositions containing sugar-functionalized nucleic acid vectors | 蒂巴生物技术有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | claimed |
| WO-2023022926-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TIBA BIOTECH LLC (US) | 2023-02-23 | — | — | WO | claimed |
| CN-115702005-A | Vectors for efficient nucleic acid delivery | 蒂巴生物技术有限公司 | 2023-02-14 | — | — | CN | claimed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | claimed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | claimed |
| EP-4387607-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | Tiba Biotech LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117897152-A | Nanoparticle compositions containing sugar-functionalized nucleic acid vectors | 蒂巴生物技术有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | Compound Solutions Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | Compound Solutions Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023022926-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TIBA BIOTECH LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-115702005-A | Vectors for efficient nucleic acid delivery | 蒂巴生物技术有限公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5240630-A | Refrigeration compositions containing diester-amides of dialkanolamines | ETHYL CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | SRM, SMS, SMOX | CA2 2235/4885CA12 3441/4885CA9 2458/4885 |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | CA2 2266/4885CA12 818/4885CA9 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.